Background Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable
population that may be susceptible to more severe COVID-19. Moreover, not only the …

Background: The most common pre-existing liver disease, the metabolic dysfunction-
associated fatty liver disease (MAFLD) formerly named as non-alcoholic fatty liver disease …

Aim Coronavirus disease 2019 (COVID-19) is a recently encountered disease that was
declared a pandemic by WHO in 2020. Obesity and other components of the metabolic …

Background: Covid-19 disease causes significant morbidity and mortality through increase
inflammation and thrombosis. Non-alcoholic fatty liver disease and non-alcoholic …

The earliest evidence from China suggested that COVID-19 patients are even more
vulnerable to succumbing from complications in the presence of a multimorbid status …

Background & Aims The coronavirus disease 2019 (COVID-19) pandemic has witnessed
more than 4.5 million deaths as of the time of writing. Whether nonalcoholic fatty liver …

Background Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease
associated with systemic changes in immune response, which might be associated with …

Background & aims Although metabolic risk factors are associated with more severe COVID-
19, there is little evidence on outcomes in patients with non-alcoholic fatty liver disease …

Background The association between metabolic-associated fatty liver disease (MAFLD) and
disease progression in patients with the coronavirus disease 2019 (COVID-19) are unclear …

Background and aims Liver involvement is common in COVID-19. Elevated aspartate and
alanine amino transaminase (AST/ALT) and borderline increase in serum bilirubin and …